Drugs / Ciliary neurotrophic factor
Ciliary neurotrophic factor
Trials 14
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT01327911 | May 2011 → Sep 2016 | macular telangiectasia | Neurotech Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01408472 | Apr 2011 → Dec 2013 | open-angle glaucoma | Jeffrey L Goldberg | Completed | No outcome recorded |
| Phase 1 | NCT01411657 | Apr 2011 → Dec 2013 | optic nerve disorder | Jeffrey L Goldberg | Completed | No outcome recorded |
| Phase 1 | NCT00063765 | Jun 2003 → Mar 2006 | retinitis pigmentosa | National Eye Institute (NEI) | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01648452 | Jul 2012 → Mar 2013 | achromatopsia | National Eye Institute (NEI) | Completed | No outcome recorded |
| Phase 28 trials · 1 met primary · 3 missed | ||||||
| Phase 2 | NCT04729972 | Jul 2021 → Dec 2022 | macular telangiectasia type 2 | Neurotech Pharmaceuticals | Completed | Met primary |
| Phase 2 | NCT04577300 | May 2021 → Aug 2025 overdue | glaucoma | Stanford University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03071965 | May 2017 → May 2021 | macular telangiectasia type 2 | Neurotech Pharmaceuticals | Completed | Missed primary |
| Phase 2 | NCT01949324 | Apr 2014 → Apr 2017 | macular telangiectasia type 2 | Neurotech Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01530659 | Jan 2012 → Jul 2019 | Usher syndrome type 2, Usher syndrome type 3, retinitis pigmentosa | Neurotech Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00447980 | Jan 2007 → Apr 2010 | retinitis pigmentosa | Neurotech Pharmaceuticals | Completed | Missed primary |
| Phase 2 | NCT00447993 | Jan 2007 → May 2009 | retinitis pigmentosa | Neurotech Pharmaceuticals | Completed | Missed primary |
| Phase 2 | NCT00447954 | Jan 2007 → May 2009 | dry age related macular degeneration | Neurotech Pharmaceuticals | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06397131 | Mar 2025 → May 2026 overdue | macular telangiectasia type 2 | Neurotech Pharmaceuticals | Active not recruiting | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ciliary Neurotrophic Factor | “The objective of this study is to evaluate the safety of ocular NT-501 device with encapsulated NT-201 cells releasing Ciliary Neurotrophic Factor (CNTF) to the retina of...” NCT01648452 ↗ |
| Known as | CNTF | “Ciliary neurotrophic factor (CNTF) implant” NCT01327911 ↗3“Ciliary neurotrophic factor (CNTF)” NCT01949324 ↗ “Ciliary neurotrophic factor (CNTF)” NCT03071965 ↗ |
| Known as | ECT-CNTF | “Patients from phase 1 RP (CNTF1); phase 2 GA (CNTF2); and phase 2 late and early stage RP (CNTF3, and CNTF4) studies received an ECT-CNTF implant, designated as "NT-501," in one eye.” PMID 23049090 ↗ Nov 2012 |
| Known as | Human ciliary neurotrophic factor | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298063 ↗ |
| Known as | Human cntf | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298063 ↗ |
| Known as | NT-501 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00063765 ↗ |
| Modality | Cell therapy | “intraocular encapsulated cell technology (ECT) implant” PMID 23049090 ↗ Nov 2012 |
| Route | Other | “by an intraocular encapsulated cell technology (ECT) implant in patients with retinitis pigmentosa (RP) and geographic atrophy (GA).” PMID 23049090 ↗ Nov 2012 |